Glenmark appoints Philip Andrew Gioia as President North America and Global API Business

He joins the Indian pharmaceutical firm from Bausch & Lomb

Glenmark Pharmaceuticals, an Indian pharmaceutical firm headquartered in Mumbai, India, has hired Philip Andrew Gioia as President North America and its Global API business.

Gioia takes responsibility for the Generics and Branded business across North America and also Global API Sales & Marketing. He will be based at Mahwah, NJ, US.

Gioia has more than 25 years of experience in the US pharmaceutical industry both in the generics and the branded space. He joins Glenmark from Bausch & Lomb (acquired by Valeant Pharmaceuticals in August), where his career spanned nearly five years, most recently as Global Head of Diversified Products and Business Development, Pharmaceuticals. Prior to that, he was Division Head of the Pharmaceutical Business Unit, North America. His responsibilities included all aspects of P&L management in addition to overall strategic commercial operations for the brand, generic and OTC divisions.

Prior to working at Bausch & Lomb, Gioia spent 13 years at Barr Pharmaceuticals, from 1995 until January 2009, when the firm was acquired by Teva Pharmaceuticals. He built Barr's branded business as VP/SVP of Sales, which included a 300+ sales force focused on Women's Health.

In 2007, Gioia was appointed Senior Vice President (SVP) of the US Generic Sales & Marketing business where he was involved in portfolio planning, manufacturing, logistics and supply chain activities. He started his pharmaceutical career with Lederle Laboratories and Forest Pharmaceuticals in various sales and marketing positions.

Companies